BTIG Maintains Buy on Guardant Health, Raises Price Target to $190

Benzinga Newsdesk www.benzinga.com Positive 82.0%

Neg 0% Neu 0% Pos 82%

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $160 to $190.